Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene

M. Boyd; S. Ross; J. Owens; D. Hunter; J. Babich; M. R. Zalutsky; T. G. Hamilton; S. Bell; R. J. Mairs

doi:10.2174/1570180043485743

Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene

M. Boyd
, S. Ross
, J. Owens
, D. Hunter
, J. Babich
, M. R. Zalutsky
, T. G. Hamilton
, S. Bell
, R. J. Mairs

Research output: Contribution to journal › Article › peer-review

Abstract

Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.

Original language	English
Pages (from-to)	50-57
Number of pages	8
Journal	Letters in Drug Design & Discovery
Volume	1
Issue number	1
DOIs	https://doi.org/10.2174/1570180043485743
Publication status	Published - 1 Jan 2004

Keywords

noradrenaline transporter
gene therapy
targeted radiotherapy
xenograft

Access to Document

10.2174/1570180043485743

Cite this

@article{b9ea74ab7b8b47b8a71d7f98c9e65949,

title = "Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene",

abstract = "Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100\% of tumours.",

keywords = "noradrenaline transporter, gene therapy, targeted radiotherapy, xenograft",

author = "M. Boyd and S. Ross and J. Owens and D. Hunter and J. Babich and Zalutsky, \{M. R.\} and Hamilton, \{T. G.\} and S. Bell and Mairs, \{R. J.\}",

year = "2004",

month = jan,

day = "1",

doi = "10.2174/1570180043485743",

language = "English",

volume = "1",

pages = "50--57",

number = "1",

}

TY - JOUR

T1 - Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene

AU - Boyd, M.

AU - Ross, S.

AU - Owens, J.

AU - Hunter, D.

AU - Babich, J.

AU - Zalutsky, M. R.

AU - Hamilton, T. G.

AU - Bell, S.

AU - Mairs, R. J.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.

AB - Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.

KW - noradrenaline transporter

KW - gene therapy

KW - targeted radiotherapy

KW - xenograft

U2 - 10.2174/1570180043485743

DO - 10.2174/1570180043485743

M3 - Article

SN - 1570-1808

VL - 1

SP - 50

EP - 57

JO - Letters in Drug Design & Discovery

JF - Letters in Drug Design & Discovery

IS - 1

ER -

Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene

Abstract

Keywords

Access to Document

Fingerprint

Cite this